The financial flow of these drugs in Sichuan Province is under investigation.

▍ drug price increases to be investigated On December 30, Sichuan Province Pharmaceutical Tender procurement service center issued "on the implementation of abnormal price changes drug production costs investigation notice."
notice shows that the drug production costs investigation by the Sichuan Provincial Health Insurance Bureau, by the Sichuan Province Drug Tender procurement service center responsible for the implementation. The scope of the
investigation includes four aspects: First, the State Medical Security Administration requires the production cost investigation of abnormally variable drugs in the price;
we can find from the above that the scope of the investigation is related to drug prices, especially drug price increases.
it is well known that many drugs have increased in price in recent years, especially some shortages and cheap drugs.
for example, Inner Mongolia Xing UNITA had previously issued a notice that two products (lidocain hydrochloride injections, musk heart pills) increased in price and one product (Lomissarin hydrochloride dropear juice) was discontinued.
for the reasons for the price increase or discontinuation of these products, the official also gave an explanation: the price increase is due to the rise in the price of raw materials, raw herbs, resulting in a substantial increase in production costs;
can be seen, the cost increase is the most commonly used reason for drug companies to increase prices, but in the end how much costs rise, the outside world is often not known, pharmaceutical companies have not used the so-called cost increases, take advantage of profit, are very opatic.
in the normal range of drug price increases is an ordinary market phenomenon, through the investigation of drug production costs, will make the reasons for drug price increases more reasonable, but also to facilitate the relevant departments targeted response and treatment of abnormal drug price increases. what is the
▍ investigation? According to the notice, the contents of this Sichuan Province survey include: "The contents of the investigation of the production cost of domestic drugs include the production cost of drugs and related production, operation, finance, product flow and price."
the investigation of the import cost of imported drugs includes the cost of import and related operation, finance, product flow and price.
we can find from the above requirements, this survey of drug production costs, but not limited to costs, but also the operation of drugs, finance, flow and other data.
in fact, there have been rumors in the industry about the cost of drug production, operation, finance, flow and so on.
recently, a letter issued by the Office of the State Health Insurance Administration on the consultation "on the current stage of drug price management notice" circulation in the industry, in which price control mentioned: "relying on the provincial drug centralized procurement, the construction of the national drug public procurement market, unified coding, standards and functional norms, to promote information interconnection, resource sharing, policy linkage, comprehensive use of monitoring and early warning, letter inquiry, cost investigation, credit evaluation, information disclosure and other means to improve the normal method of monitoring and monitoring,"
for drugs with price increases or frequency anomalies, large regional price differences, serious adverse distribution situations, large differences in online and offline prices and multiple consecutive early warning areas, the medical insurance department may contact the operators, ask the operators to explain the situation in writing, the circumstances are serious, the impact is bad, may formally interview enterprises, require pharmaceutical companies to prove the reasons for the change, provide information on production, operation, finance and flow related to drug costs. if the
enterprisevoluntarily undertakes to adjust the price of medicines to a reasonable range, it shall submit a written letter of commitment to the medical security department and adjust it to the place within the prescribed time. If the
enterprise refuses to adjust without justifiable reasons, it shall, according to its seriousness, take credit punishment, joint law enforcement and other means of punishment according to its seriousness.
with the Sichuan Province to carry out abnormal price changes drug production costs survey, I believe that the provinces will follow up on the work.
the future, drug prices, production costs, operations and flow of information, will achieve "naked run", then, all non-compliant sales behavior will be nowhere to hide, all unreasonable price increases will also be cut.
will be another severe blow for pharmaceutical companies that are falsely inflated costs, driven up spending, operate spent illegally, and have low cost control and confusing price controls.
.